Cellectis (CLLS) Net Cash Flow Growth (3y) (2018 - 2026)
Cellectis (CLLS) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Cellectis | 288.51 Mn | 102.85 Mn | - | -56.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.22% |
| Dec 31, 2025 | 13.88% |
| Sep 30, 2025 | 29.03% |
| Jun 30, 2025 | -59.69% |
| Mar 31, 2025 | 20.10% |
| Dec 31, 2024 | 27.37% |
| Sep 30, 2024 | 32.69% |
| Jun 30, 2024 | -15.60% |
| Mar 31, 2024 | 24.12% |
| Dec 31, 2023 | 55.65% |
| Sep 30, 2023 | -32.27% |
| Jun 30, 2023 | 72.07% |
| Mar 31, 2023 | 47.86% |
| Dec 31, 2022 | 35.64% |
| Sep 30, 2022 | 19.26% |
| Jun 30, 2022 | 12.92% |
| Mar 31, 2022 | -5.87% |
| Dec 31, 2021 | -16.95% |
| Sep 30, 2021 | -107.46% |
| Jun 30, 2021 | -44.67% |